Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant hormone-positive breast cancer with FGFR alterationsNoelia Martínez-Jáñez, Miguel Quintela-Fandiño, Rodrigo Sánchez-Bayona et al.|npj Precision Oncology|2025Cited by 3
p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor–positive breast cancerSilvana Mourón, Miguel Quintela-Fandiño, María J. Bueno et al.|JNCI Cancer Spectrum|2023Cited by 2
Abstract OT2-19-08: Phase IB/II trial of palbociclib and binimetinib in advanced triple-negative breast cancer with hyperactivation of ERK and/or CDK4/6Luís Manso, Miguel Quintela-Fandiño, Alfonso Cortés et al.|Cancer Research|2022Cited by 1
Abstract P5-02-28: p27Kip1 V109G single-nucleotide polymorphism (SNP): pinpointing the hormone-receptor positive breast cancer subpopulation that requires CDK4/6 inhibitors in addition to endocrine therapyMiguel Quintela-Fandiño, Marcos Malumbres, María J. Bueno et al.|Cancer Research|2023Cited by 0
Abstract PS12-07: Phase II clinical trial of palbociclib and binimetinib in advanced triple-negative breast cancer (TNBC) with hyperactivation of ERK and/or CDK4/6Rodrigo Sánchez-Bayona, Miguel Quintela-Fandiño, Alfonso Cortés et al.|Cancer Research|2024Cited by 0